Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing

  • Trujillano, Daniel
  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Ossowski, Stephan|||0000-0002-7416-9568
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Estivill, Xavier|||0000-0002-0723-2256
  • Ars, Elisabet|||0000-0002-4118-4358
Molecular diagnostics of autosomal dominant polycystic kidney disease (ADPKD) relies on mutation screening of PKD1 and PKD2, which is complicated by extensive allelic heterogeneity and the presence of six highly homologous sequences of PKD1. To date, specific sequencing of PKD1 requires laborious long-range amplifications. The high cost and long turnaround time of PKD1 and PKD2 mutation analysis using conventional techniques limits its widespread application in clinical settings. We performed targeted next-generation sequencing (NGS) of PKD1 and PKD2. Pooled barcoded DNA patient libraries were enriched by in-solution hybridization with PKD1 and PKD2 capture probes. Bioinformatics analysis was performed using an in-house developed pipeline. We validated the assay in a cohort of 36 patients with previously known PKD1 and PKD2 mutations and five control individuals. Then, we used the same assay and bioinformatics analysis in a discovery cohort of 12 uncharacterized patients. We detected 35 out of 36 known definitely, highly likely, and likely pathogenic mutations in the validation cohort, including two large deletions. In the discovery cohort, we detected 11 different pathogenic mutations in 10 out of 12 patients. This study demonstrates that laborious long-range PCRs of the repeated PKD1 region can be avoided by in-solution enrichment of PKD1 and PKD2 and NGS. This strategy significantly reduces the cost and time for simultaneous PKD1 and PKD2 sequence analysis, facilitating routine genetic diagnostics of ADPKD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeted next-generation sequencing in steroid-resistant nephrotic syndrome, mutations in multiple glomerular genes may influence disease severity

  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Trujillano, Daniel
  • Santín, Sheila
  • Ossowski, Stephan|||0000-0002-7416-9568
  • Mendizábal, Santiago
  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • Madrid, Alvaro
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Estivill, Xavier|||0000-0002-0723-2256
  • Ars, Elisabet|||0000-0002-4118-4358
Genetic diagnosis of steroid-resistant nephrotic syndrome (SRNS) using Sanger sequencing is complicated by the high genetic heterogeneity and phenotypic variability of this disease. We aimed to improve the genetic diagnosis of SRNS by simultaneously sequencing 26 glomerular genes using massive parallel sequencing and to study whether mutations in multiple genes increase disease severity. High-throughput mutation analysis was performed in 50 SRNS and/or focal segmental glomerulosclerosis (FSGS) patients, a validation cohort of 25 patients with known pathogenic mutations, and a discovery cohort of 25 uncharacterized patients with probable genetic etiology. In the validation cohort, we identified the 42 previously known pathogenic mutations across NPHS1, NPHS2, WT1, TRPC6, and INF2 genes. In the discovery cohort, disease-causing mutations in SRNS/FSGS genes were found in nine patients. We detected three patients with mutations in an SRNS/FSGS gene and COL4A3. Two of them were familial cases and presented a more severe phenotype than family members with mutation in only one gene. In conclusion, our results show that massive parallel sequencing is feasible and robust for genetic diagnosis of SRNS/FSGS. Our results indicate that patients carrying mutations in an SRNS/FSGS gene and also in COL4A3 gene have increased disease severity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated

  • Cabrera-López, Cristina
  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Martí, Teresa
  • Català, Violeta
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Bissler, John|||0000-0001-9685-9183
  • Harris, Peter C.
  • Ars, Elisabet|||0000-0002-4118-4358
  • Torra Balcells, Roser|||0000-0001-8714-2332
Mutations in TSC1 or TSC2 cause the tuberous sclerosis complex (TSC), while mutations in PKD1 or PKD2 cause autosomal dominant polycystic kidney disease (ADPKD). PKD1 lays immediately adjacent to TSC2 and deletions involving both genes, the PKD1/TSC2 contiguous gene syndrome (CGS), are characterized by severe ADPKD, plus TSC. mTOR inhibitors have proven effective in reducing angiomyolipoma (AML) in TSC and total kidney volume in ADPKD but without a positive effect on renal function. We describe a patient with independent truncating PKD1 and TSC2 mutations who has the expected phenotype for both diseases independently instead of the severe one described in PKD1/TSC2 -CGS. Treatment with mTOR inhibitors reduced the AML and kidney volume for 2 years but thereafter they resumed growth; no positive effect on renal function was seen throughout. This is the first case addressing the response to mTOR treatment when independent truncating mutations in PKD1 and TSC2 are present. This case reveals that although PKD1 and TSC2 are adjacent genes and there is likely cross-talk between the PKD1 and TSC2 signalling pathways regulating mTOR, having independent TSC2 and PKD1 mutations can give rise to a milder kidney phenotype than is typical in PKD1/TSC2 -CGS cases. A short-term beneficial effect of mTOR inhibition on AML and total kidney volume was not reflected in improved renal function.